hypertonic dextrose water
PreclinicalSmall molecule
hypertonic dextrose water is one of 17 small molecule programs targeting Bursitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Bursitis
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Aleve
Alnylam PharmaceuticalsApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Voltaren
CCerimon Pharmaceuticals
Phase 3
Experimental
BiogenPhase 2
MRX-7EAT
MMEDRx USA, Inc.
Phase 3
FX006
Pacira Pharmaceuticals, IncPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hypertonic dextrose water. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details